Danirixin
10mM in DMSO
- Product Code: 168992
CAS:
954126-98-8
| Molecular Weight: | 441.9 g./mol | Molecular Formula: | C₁₉H₂₁ClFN₃O₄S |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20°C |
Product Description:
Danirixin is primarily investigated for its potential in treating respiratory conditions, particularly chronic obstructive pulmonary disease (COPD). It functions as a selective CXCR2 antagonist, which means it blocks the activity of the CXCR2 receptor involved in the migration of neutrophils to sites of inflammation. By inhibiting this pathway, Danirixin helps reduce neutrophil-driven inflammation in the airways, a key factor in the progression of COPD and other inflammatory lung diseases.
It has been studied in clinical trials to evaluate its ability to reduce exacerbations and improve lung function in patients with COPD, especially those with a history of frequent flare-ups. Due to its targeted mechanism, Danirixin may offer benefits over broader anti-inflammatory treatments by minimizing systemic side effects. Research into its use remains focused on respiratory therapeutics, with potential applications in asthma and bronchiectasis where neutrophilic inflammation plays a role.
Sizes / Availability / Pricing:
| Size | Availability | Price | Quantity |
|---|---|---|---|
| 1ml | 10-20 days | ฿6,840.00 |
+
-
|
Danirixin
Danirixin is primarily investigated for its potential in treating respiratory conditions, particularly chronic obstructive pulmonary disease (COPD). It functions as a selective CXCR2 antagonist, which means it blocks the activity of the CXCR2 receptor involved in the migration of neutrophils to sites of inflammation. By inhibiting this pathway, Danirixin helps reduce neutrophil-driven inflammation in the airways, a key factor in the progression of COPD and other inflammatory lung diseases.
It has been studied in clinical trials to evaluate its ability to reduce exacerbations and improve lung function in patients with COPD, especially those with a history of frequent flare-ups. Due to its targeted mechanism, Danirixin may offer benefits over broader anti-inflammatory treatments by minimizing systemic side effects. Research into its use remains focused on respiratory therapeutics, with potential applications in asthma and bronchiectasis where neutrophilic inflammation plays a role.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Purchase History for
Loading purchase history...
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :